Microbiome as a potential key to better treatment: Clinical study on new therapy for Crohn’s disease (EurekAlert)

Researchers at the Technical University of Munich and LMU University Hospital Munich have uncovered how exclusive enteral nutrition (EEN), a liquid diet used to manage Crohn’s disease, reduces inflammation by altering the gut microbiome. Their study found that medium-chain fatty acids in the formula promote beneficial gut bacteria, preventing inflammation. To extend the benefits of EEN, a clinical trial will test whether combining it with fecal microbiome transfer can sustain remission. If successful, this approach could revolutionize Crohn’s disease treatment by establishing a healthier, long-term gut microbiome.